Fibroblast growth factor-23 may serve as a novel biomarker for renal osteodystrophy progression

  • Authors:
    • Si Yan Liu
    • Dong Dong Zhang
    • Yang Fang Wu
    • Huang Huang Luo
    • Guang Mei Jiang
    • Yao Xu
    • Yue Wu
    • Xun Xia
    • Wei Wei
    • Bo Hu
    • Peng Hu
  • View Affiliations

  • Published online on: October 15, 2018     https://doi.org/10.3892/ijmm.2018.3934
  • Pages: 535-546
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of the present study was to determine whether fibroblast growth factor (FGF)‑23 could serve as a novel biomarker for renal osteodystrophy (ROD) progression. A rat model of ROD was induced by left nephrectomy plus intravenous injection of Adriamycin. Serum FGF‑23 was determined using an enzyme‑linked immunosorbent assay. Serum level and bone expression of FGF‑23 were both significantly elevated in the ROD group at 24 h post‑surgery. Serum FGF‑23 was negatively correlated with calcium, phosphate, 25‑hydroxyvitamin D, conventional bone biomarkers and bone collagen X. More importantly, serum FGF‑23 was significantly associated with abnormalities in bone formation rate, osteoblasts, osteoclasts, trabecular volume thickness and osteoid volume. Therefore, FGF‑23 may serve as a novel biomarker for ROD.
View Figures
View References

Related Articles

Journal Cover

January 2019
Volume 43 Issue 1

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Liu, S.Y., Zhang, D.D., Wu, Y.F., Luo, H.H., Jiang, G.M., Xu, Y. ... Hu, P. (2019). Fibroblast growth factor-23 may serve as a novel biomarker for renal osteodystrophy progression. International Journal of Molecular Medicine, 43, 535-546. https://doi.org/10.3892/ijmm.2018.3934
MLA
Liu, S. Y., Zhang, D. D., Wu, Y. F., Luo, H. H., Jiang, G. M., Xu, Y., Wu, Y., Xia, X., Wei, W., Hu, B., Hu, P."Fibroblast growth factor-23 may serve as a novel biomarker for renal osteodystrophy progression". International Journal of Molecular Medicine 43.1 (2019): 535-546.
Chicago
Liu, S. Y., Zhang, D. D., Wu, Y. F., Luo, H. H., Jiang, G. M., Xu, Y., Wu, Y., Xia, X., Wei, W., Hu, B., Hu, P."Fibroblast growth factor-23 may serve as a novel biomarker for renal osteodystrophy progression". International Journal of Molecular Medicine 43, no. 1 (2019): 535-546. https://doi.org/10.3892/ijmm.2018.3934